Afatinib

Afatinib
Clinical data
Trade names	Gilotrif, Giotrif, Afanix
Other names	BIBW 2992
AHFS/Drugs.com	Monograph
MedlinePlus	a613044
License data	EU EMA: by INN; US DailyMed: Afatinib;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	L01EB03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	95%
Metabolism	CYP not involved
Elimination half-life	37 hours
Excretion	Faeces (85%), urine (4%)
Identifiers
	IUPAC name N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide;
CAS Number	850140-72-6 [Drugbank];
PubChem CID	10184653;
IUPHAR/BPS	5667;
DrugBank	DB08916 ;
ChemSpider	8360155 ;
UNII	41UD74L59M;
KEGG	D09724 ; as salt: D09733 ;
ChEBI	CHEBI:61390 ;
ChEMBL	ChEMBL1173655 ;
CompTox Dashboard (EPA)	DTXSID20893451 ;
ECHA InfoCard	100.239.035
Chemical and physical data
Formula	C24H25ClFN5O3
Molar mass	485.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C\C=C\C(=O)Nc3cc1c(Nc(cc2Cl)ccc2F)ncnc1cc3OC4COCC4;
	InChI InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 ; Key:ULXXDDBFHOBEHA-CWDCEQMOSA-N ;
	(what is this?) (verify)

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

It is mainly used to treating cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.